Ventures
Invest in breakthrough healthtech solutions that transform patients' lives.

Receive the latest investment opportunities that match your interests, directly in your inbox. Stay informed and never miss out.
a highlight from our portfolio

Angiogenesis Analytics

PEP Health
Capnosway introduces a CO2 monitoring device designed to address the shortcomings of traditional anesthesia. Developed by Philips, this solution directly measures CO2 concentration at the patient's mouth or nose without the need for air sampling. By eliminating procedures, and potential errors associated, Capnosway ensures accurate and efficient monitoring for medical professionals.
.webp)
Nilocas offers a revolutionary solution for detecting coronary artery disease non-invasively and without radiation. Patients wear a lightweight chest patch that captures the sounds of turbulent blood flow through arteries using microphones and accelerometers. Advanced machine learning and AI rapidly analyze the data, providing a clear diagnosis in just 10 minutes. This innovation eliminates the need for costly and invasive procedures, making cardiac diagnosis more accessible in both clinical and non-clinical settings.

Angiogenesis Analytics, offers an ultrasound-based solution for detecting, localizing, and characterizing prostate cancer. Each year, over 1.5 million men undergo invasive biopsies with risks of infection, false negatives, and overtreatment. Angiogenesis Analytics eliminates these issues by providing a non-invasive, accurate, and cost-effective alternative, improving patient comfort and outcomes. With an estimated market value of USD 450 million annually, Angiogenesis Analytics addresses a significant global need for better prostate cancer diagnostics.

ProVascTec offers a novel solution for chronic arterial disease, focusing on peripheral arterial disease (PAD) and chronic limb ischemia. Unlike traditional treatments like angioplasty or bypass surgery, ProVascTec aims to stimulate vascular tissue growth using mesenchymal stem cells, reducing complications and improving blood flow. This innovative approach has the potential to benefit millions of patients suffering from PAD worldwide.

Karla Therapeutics is exploring an approach, treating mental disorders by leveraging our immune system. Neurodevelopmental disorders like ADHD and OCD are increasingly prevalent, yet treatment options often have side effects and limited effectiveness. By bridging between the immune system and mental health, Karla aims to revolutionize treatment methods. Their research focuses on a specific protein identified by top-tier immunologists, showing promising results in early experiments for OCD, anxiety, and ADHD.

ChARM, or the Children’s Automated Respiration Monitor, addresses the challenge of pneumonia misdiagnosis in low-resource settings. This battery-powered device provides accurate breathing rate monitoring for children under five, empowering healthcare workers to make correct diagnoses swiftly. By streamlining the diagnostic process, ChARM facilitates timely treatment, potentially saving thousands of young lives annually.

MindAffect aims to diagnose visual and hearing impairments in over 2 billion people, including children, seniors, and the disabled, leading to untreated impairments and significant societal costs. Their innovative brain computer interface and AI technology offer a solution by analyzing brain responses to auditory or visual stimuli, reducing testing time and improving accuracy.

Ecomedic is dedicated to helping hospitals reduce their carbon footprint, addressing the healthcare sector's contribution to global emissions. Ecomedic's database and software tools enable environmental impact analyses, identify sources of emissions and measures the effect of alternative solutions. By providing insights and solutions, the institutions are supported in achieving their carbon neutrality goals and reducing operational costs.

Our impact
Explore our 2024 Impact report

Invest in a portfolio of companies
